Elutia

Next Generation Biologics Will Transform Global Regenerative Care

AnalystHighTarget

Not Invested

Consensus Narrative from 2 Analysts

Published

24 Aug 25

Updated

24 Aug 25

AnalystHighTarget's Fair Value

US$8.00

70.0% undervalued

24 Aug

US$2.40

-39.8%

18.8%

-39.8%

18.8%

Author's Valuation

US$8.0

70.0% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$8.0

70.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

51.27%

Biotech revenue growth rate

11.84%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.09%

Calculation

US$10.63m

Earnings '28

72.43x

PE Ratio '28

US$770.19m

Market Cap '28

US$770.19m

Market Cap '28

78.25m

No. shares '28

US$9.84

Share Price '28

US$9.84 Share Price '28

Discounted to 2025 @ 7.16% p.a.

US$8.00

Fair Value '25